论文部分内容阅读
[目的]对比分析通心络与曲美他嗪治疗无症状心肌缺血的临床疗效,以为治疗无症状心肌缺血提供方法参照。[方法]将80例随机分为治疗组与对照组,每组40例。对照组口服通心络;治疗组口服曲美他嗪。比较两组治疗前后ST段压低次数和ST段压低可持续时间情况,以及整体疗效和副反应情况。治疗1疗程后判定疗效[结果]在ST段压低情况下,治疗后治疗组在ST段压低次数以及ST段压低可持续时间上下降幅度更为明显。另外,治疗组比对照组副反应小。治疗组临床疗效优于对照组(P<0.05)。[结论]在治疗无症状心肌缺血中,通心络较之曲美他嗪药效作用更快,副反应更小,整体治疗效果更佳,更值得临床推广。
[Objective] To compare and analyze the clinical curative effect of Tongxinluo and trimetazidine in the treatment of asymptomatic myocardial ischemia in order to provide reference for the treatment of asymptomatic myocardial ischemia. [Methods] 80 cases were randomly divided into treatment group and control group, 40 cases in each group. The control group oral Tongxinluo; treatment group oral trimetazidine. The number of ST segment depression and ST segment depression duration before and after treatment were compared between the two groups, and the overall efficacy and side effects were compared. Therapeutic effect was determined after 1 course of treatment [Results] The decrease in the number of ST segment depression and the duration of ST segment depression was more pronounced in the treatment group after ST depression. In addition, the treatment group than the control group side effects. The clinical efficacy of the treatment group was better than that of the control group (P <0.05). [Conclusion] In the treatment of asymptomatic myocardial ischemia, Tongxinluo compared with trimetazidine efficacy faster, less side effects, the overall treatment effect is better, more worthy of clinical promotion.